Clinical trials: Ovarian Cancer (OvCa), active
Ovarian Cancer, Ovarian Carcinoma, Recurrent
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Ovarian, fallopian tube, and peritoneal cancers are often diagnosed at an advanced stage, requiring chemotherapy. Recently, the standard treatment, platinum-based chemotherapy plus PARP inhibitors, has extended disease-free…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent, Ovarian Cancer (OvCa)
- Trial name
- TROY (NCT07340164)
- Testing
- Trastzumab Deruxtecan, Bevacizumab, Platinum Based Chemotherapy
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- Yonsei University
Ovarian Cancer
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for…
- Trial name
- ASPENOVA (NCT07546500)
- Testing
- Investigator's choice of Chemotherapy, Azenosertib
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 420 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Advanced Ovarian Cancer
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
Surgery and chemotherapy combined constitute first line treatment in women with advanced ovarian cancer. The aim of surgery apart from staging is cytoreduction, i.e. surgical resection of tumour.
- Trial name
- IPLA-OVCA (NCT04065009)
- Testing
- Ropivacaine, Saline Solution
- Where
- Sweden
- Volunteers
- 220 people
- Sponsor
- Karolinska Institutet
Ovarian Cancer (OvCa), Ovarian Cancer Metastatic
O-RADS MRI System on Early Detection of Ovarian Cancer
This study is designed to prospectively enroll individuals with suspected or potential risk of ovarian cancer across multiple centers.
- Trial name
- NCT07009743
- Testing
- MRI contrast-enhancing agents
- Where
- China
- Volunteers
- 2,549 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Ovarian Cancer (OvCa), Recurrent Ovarian Cancer
Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer
The goal of this clinical trial is to investigate if CALM-TF (Trauma-Focused Managing Cancer and Living Meaningfully) is effective in treating traumatic stress symptoms in women with advanced ovarian cancer.
- Trial name
- CALM-TF (NCT07286162)
- Testing
- Trauma-Focused Managing Cancer and Living Meaningfully
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- University Health Network, Toronto
Ovarian Cancer (OvCa)
Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression
The goal of this observational study is to determine the urinary proteomic characteristics in women with and without ovarian cancer. The main questions it aims to answer are: 1.
- Trial name
- NCT06760923
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Xiangya Hospital of Central South University
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Ovarian Cancer, Ovarian Cancer (OvCa)
Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer
Involvement of the infundibulopelvic ligament in ovarian cancer may be associated with decreased survival and related to paraaortic lymph node metastasis
- Conditions
- Ovarian Cancer, Ovarian Cancer (OvCa), Ovarian Adenocarcinoma
- Trial name
- INFPELV (NCT07100288)
- Testing
- resection of infundibulopelvic ligament
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Complejo Hospitalario Universitario Insular Materno Infantil
Ovarian Cancer (OvCa)
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in…
- Trial name
- RESO (NCT07586449)
- Testing
- Senaparib capsules(20mg)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
Platinum Resistant Ovarian Cancer, Platinum Refractory Epithelial Ovarian Cancer
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
This study is a Prospective, Single-arm, Phase II clinical trial. The purpose of this study is to find out if taking Etoposide Capsules combined With Bevacizumab and Iparomlimab and Tuvonralimab is safe and works well for people…
- Conditions
- Platinum Resistant Ovarian Cancer, Platinum Refractory Epithelial Ovarian Cancer, Ovarian Cancer (OvCa)
- Trial name
- NCT07117877
- Testing
- Etoposide Capsules, Bevacizumab, Iparomlimab and Tuvonralimab (QL1706)
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Fudan University
Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying study about safety and efficacy of maintenance DCVAC/OvCa after first-line chemotherapy added to standard of care in patients with newly…
- Conditions
- Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT04834544
- Testing
- DCVAC/OvCa
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Peking University Third Hospital
Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa)
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail…
- Conditions
- Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa), Kidney Cancers, Bladder Cancer
- Trial name
- NCT07050771
- Testing
- Comprehensive multimodal prehabilitation (CMMP)
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- The Methodist Hospital Research Institute
Ovarian Cancer (OvCa)
Rectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer
Colorectum is the most common site of metastasis in ovarian cancer. Regarding intestinal surgery, there is controversy over whether to choose bowel resection or tumor removal, and currently, there are no prospective randomized…
- Trial name
- RSEnTrail (NCT07616310)
- Testing
- Rectosigmoid Lesion Excision +tumor cell debulking surgery, Rectosigmoid Resection +tumor cell debulking surgery
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine